Acorda Therapeutics, Inc. (ACOR)
-NasdaqGS 34.92 
0.03(0.09%) 03:11 SGT - Nasdaq Real Time Price
| Prev Close: | 34.95 |
|---|
| Open: | 35.06 |
|---|
| Bid: | 34.93 x 300 |
|---|
| Ask: | 35.00 x 300 |
|---|
| 1y Target Est: | 39.65 |
|---|
| Beta: | 1.32 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 34.68 - 35.12 |
|---|
| 52wk Range: | 21.33 - 40.87 |
|---|
| Volume: | 193,637 |
|---|
| Avg Vol (3m): | 443,966 |
|---|
| Market Cap: | 1.39B |
|---|
| P/E (ttm): | 9.62 |
|---|
| EPS (ttm): | 3.63 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 5 Stocks Poised for Breakoutsat TheStreet(Sat, 8 Jun)
- ACORDA THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VotEDGAR Online(Tue, 4 Jun)
- 2 Buys, 1 Sell In This Year's Biotech Surgeat Seeking Alpha(Thu, 30 May)
- New Memoir by Singer/Songwriter Kristie Salerno Kent Follows Her Journey as a Multiple Sclerosis Patient AdvocateBusiness Wire(Wed, 29 May)
- Acorda to Present New Research on AMPYRA® at Fifth Cooperative Meeting of CMSC and ACTRIMSBusiness Wire(Tue, 28 May)
- ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, 28 May)
- Alkermes Earnings Beat Estimates, But Outlook Unclearat Investor's Business Daily(Fri, 24 May)
- Alkermes posts 4Q profit as royalty payments riseAP(Fri, 24 May)
- Alkermes posts 4Q profit as royalty payments riseAP(Fri, 24 May)
- Alkermes Earnings Seen Rising, But Sales Uncertainat Investor's Business Daily(Thu, 23 May)
Key Statistics
| Forward P/E (1 yr): | 39.70 |
|---|
| P/S (ttm): | 4.55 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.27 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.09 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 6.27 |
|---|
Business Summary
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorde...
View More